ASND vs AXSM
Ascendis Pharma A/S and Axsome Therapeutics, Inc., both Healthcare
Ascendis Pharma A/S is the larger company at $15B against $13B. Over the past year AXSM returned +99% against +32% for ASND. Ryufin's sector-relative Smart Score puts AXSM ahead, 9/10 against 8/10.
| Figure | ASND | AXSM |
|---|---|---|
| Last close | $250 | $207 |
| Market cap | $15B | $13B |
| 1-year return | +32% | +99% |
| 5-year return | +108% | +312% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 9/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Ascendis Pharma A/S
Revenue of $248M in Q4 2025, net income null.
Axsome Therapeutics, Inc.
Revenue of $218M in Q2 2026, net income null. Its largest reported line is Royalty And Milestone, 66% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.